J&J beats lawsuit alleging Tylenol defect; Valeant has made billions for others than Ackman;

@FiercePharma: India pharma sees trouble for its industry in newly negotiated TPP. More | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. News | Follow @EricPFierce

@CarlyHFierce: After FDA snub, AZ diabetes combo faces potential years-long delay. Article | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) has won the first lawsuit to go to trial alleging its Extra Strength Tylenol was defectively designed. Story

> Ackman is not the only hedge fund operator who has made billions of dollars from shares in Valeant Pharmaceuticals. Forbes post

> The global market for treating peripheral artery disease (PAD) is expected to peak at nearly in 2020 before falling off as generics undercut sales of Brilinta and Xarelto. Story

> A state judge has ruled that Arizona's law restricting the use of morning after pills violates the state's constitution. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: 23andMe adds chapter to comeback story with $115M in funding. Report | Follow @EmilyWFierce

> Theranos dials down lab testing amid FDA pushback. Story

> WSJ: Former Theranos employees reveal problems with proprietary testing device. More

Biotech News

@FierceBiotech: FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand. More | Follow @FierceBiotech

@JohnCFierce: Zafgen hammered (again) as FDA clamps partial hold on PhIII obesity drug. Report | Follow @JohnCFierce

@DamianFierce: Lost in all this is that "Theranos" would have been a great name for a black metal band. | Follow @DamianFierce

> Biotech notches another $2B VC quarter, but can it last? More

> PTC's muscular dystrophy drug fails another key test with approval on the line. Article

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.